Leiters to serve as a contracted 503B compounded pharmaceutical supplier to ROi’s membership DENVER- Leiters, an FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services, announced today that they have been awarded an outsourcing supply agreement for 503B compounded pharmaceuticals. The 3-year agreement went into effect on June 1, 2018. ROi serves more […]
Leiters to serve as a contracted 503B compounded pharmaceutical supplier to ROi’s membership
DENVER- Leiters, an FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services, announced today that they have been awarded an outsourcing supply agreement for 503B compounded pharmaceuticals. The 3-year agreement went into effect on June 1, 2018.
ROi serves more than 300 hospitals and 2,800 non-acute facilities across the U.S. Through the agreement, ROi’s members will have access to the Leiters portfolio of high quality patient medications.
Leiters was awarded the agreement after passing ROi’s rigorous onsite quality audit of its new Denver, Colorado 503B cGMP facility.
Moving forward, Leiters and ROi will also collaborate on new product development and work together to address market shortages in order to better serve ROi members and the communities they serve.
“Our mission at Leiters is to deliver better medicine to more people. We are excited to provide high quality products and services to the ROi members and their patients,” said Robin Smith Hoke, Chief Executive Officer of Leiters.
Leiters to serve as a contracted 503B compounded pharmaceutical supplier to ROi’s membership
DENVER- Leiters, an FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services, announced today that they have been awarded an outsourcing supply agreement for 503B compounded pharmaceuticals. The 3-year agreement went into effect on June 1, 2018.
ROi serves more than 300 hospitals and 2,800 non-acute facilities across the U.S. Through the agreement, ROi’s members will have access to the Leiters portfolio of high quality patient medications.
Leiters was awarded the agreement after passing ROi’s rigorous onsite quality audit of its new Denver, Colorado 503B cGMP facility.
Moving forward, Leiters and ROi will also collaborate on new product development and work together to address market shortages in order to better serve ROi members and the communities they serve.
“Our mission at Leiters is to deliver better medicine to more people. We are excited to provide high quality products and services to the ROi members and their patients,” said Robin Smith Hoke, Chief Executive Officer of Leiters.
